|
| HOME | SUBSCRIPTIONS | CURRENT ISSUE | PAST ISSUES | CARDIOSOURCE | SEARCH | HELP | FEEDBACK |
|
|
|
|||||||||
|
|||||||||||
|
J Am Coll Cardiol, 2002; 40:1414-1421 © 2002 by the American College of Cardiology Foundation |
* ANMCO Research Center, Florence, Italy
Veterans Affairs Medical Center, Minneapolis, Minnesota, USA
Mid-Atlantic Cardiovascular Consultants, P.A., Baltimore, Maryland, USA
Mario Negri Institute, Milan, Italy
|| University of Minnesota, Minneapolis, Minnesota, USA
Manuscript received January 14, 2002; revised manuscript received April 12, 2002, accepted April 17, 2002.
* Reprint requests and correspondence: Dr. Aldo P. Maggioni, GISSI Group, ANMCO Research Center, Via La Marmora 34, 50121 Florence, Italy.
maggioni{at}anmco.it
OBJECTIVES: A subgroup analysis of the Valsartan Heart Failure Trial (Val-HeFT) was performed to evaluate the effects of the angiotensin II receptor blocker, valsartan, in the patients with chronic heart failure (HF) not receiving angiotensin-converting enzyme (ACE) inhibitors.
BACKGROUND: The ACE inhibitors reduce mortality and morbidity in patients with HF. Nonetheless, nearly 20% of potentially eligible patients may not be prescribed ACE inhibitors.
RESULTS: Val-HeFT was an international, randomized, double-blinded trial that compared valsartan with placebo when added to the prescribed treatment of patients with HF. The two primary end points of the study were all-cause mortality and the composite of all-cause mortality and morbidity (sudden death with resuscitation, hospital admission for HF, or administration of intravenous inotropic or vasodilator drugs for 
4 h without hospital admission). Of the 5,010 patients enrolled in the trial, 366 (7.3%) were not treated with ACE inhibitors at baseline. The effects of valsartan on the primary and secondary end points of the study were assessed in this subgroup of patients.
RESULTS: Both all-cause mortality and combined mortality and morbidity for patients not treated with ACE inhibitors were significantly reduced in the valsartan treatment group compared with the placebo group (17.3% vs. 27.1%, p = 0.017 and 24.9% vs. 42.5%, p < 0.001, respectively). Consistent with the data on clinical events, patients randomized to valsartan showed improvements in physiologic variables, such as ejection fraction, left ventricular internal diameter in diastole, and plasma neurohormone levels. Permanent discontinuation of study treatment because of adverse experiences was comparable between the two groups.
CONCLUSIONS: Val-HeFT has provided the first placebo-controlled outcome data demonstrating a favorable effect of an angiotensin receptor blocker on mortality and morbidity in patients with HF not treated with ACE inhibitors. Based on these results, valsartan appears to be an effective therapy in ACE inhibitor-intolerant patients.
| ||||||||||||||||||||||
This article has been cited by other articles:
|
|
 |
|
  E. Caglayan, B. Stauber, A. R. Collins, C. J. Lyon, F. Yin, J. Liu, S. Rosenkranz, E. Erdmann, L. E. Peterson, R. S. Ross, et al. Differential Roles of Cardiomyocyte and Macrophage Peroxisome Proliferator-Activated Receptor {gamma} in Cardiac Fibrosis Diabetes, September 1, 2008; 57(9): 2470 - 2479. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Ferdinandy, R. Schulz, and G. F. Baxter Interaction of Cardiovascular Risk Factors with Myocardial Ischemia/Reperfusion Injury, Preconditioning, and Postconditioning Pharmacol. Rev., December 1, 2007; 59(4): 418 - 458. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. O. Phillips, A. Kashani, D. K. Ko, G. Francis, and H. M. Krumholz Adverse Effects of Combination Angiotensin II Receptor Blockers Plus Angiotensin-Converting Enzyme Inhibitors for Left Ventricular Dysfunction: A Quantitative Review of Data From Randomized Clinical Trials Arch Intern Med, October 8, 2007; 167(18): 1930 - 1936. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A D Struthers Angiotensin blockade or aldosterone blockade as the third neuroendocrine-blocking drug in mild but symptomatic heart failure patients Heart, December 1, 2006; 92(12): 1728 - 1731. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. McMurray and K. Swedberg Treatment of chronic heart failure: a comparison between the major guidelines Eur. Heart J., August 1, 2006; 27(15): 1773 - 1777. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. S. Go, J. Yang, L. M. Ackerson, K. Lepper, S. Robbins, B. M. Massie, and M. G. Shlipak Hemoglobin Level, Chronic Kidney Disease, and the Risks of Death and Hospitalization in Adults With Chronic Heart Failure: The Anemia in Chronic Heart Failure: Outcomes and Resource Utilization (ANCHOR) Study Circulation, June 13, 2006; 113(23): 2713 - 2723. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Lechat The evolution of heart failure management over recent decades: from CONSENSUS to CIBIS Eur. Heart J. Suppl., June 1, 2006; 8(suppl_C): C5 - C12. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. P Liu, A. Maggioni, and E. J Velazquez Use of Valsartan in Post-Myocardial Infarction and Heart Failure Patients Journal of Renin-Angiotensin-Aldosterone System, March 1, 2006; 7(1_suppl): S19 - S22. [Abstract] [PDF]
|
|
|
|
|
|
M. Tendera Epidemiology, treatment, and guidelines for the treatment of heart failure in Europe Eur. Heart J. Suppl., October 1, 2005; 7(suppl_J): J5 - J9. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. J.V. McMurray The role of angiotensin II receptor blockers in the management of heart failure Eur. Heart J. Suppl., October 1, 2005; 7(suppl_J): J10 - J14. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. P. Maggioni Review of the new ESC guidelines for the pharmacological management of chronic heart failure Eur. Heart J. Suppl., October 1, 2005; 7(suppl_J): J15 - J20. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. S. Anand, M. A. Kuskowski, T. S. Rector, V. G. Florea, R. D. Glazer, A. Hester, Y. T. Chiang, N. Aknay, A. P. Maggioni, C. Opasich, et al. Anemia and Change in Hemoglobin Over Time Related to Mortality and Morbidity in Patients With Chronic Heart Failure: Results From Val-HeFT Circulation, August 23, 2005; 112(8): 1121 - 1127. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Authors/Task Force Members, K. Swedberg, Writing Committee:, J. Cleland, H. Dargie, H. Drexler, F. Follath, M. Komajda, L. Tavazzi, O. A. Smiseth, et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology Eur. Heart J., June 1, 2005; 26(11): 1115 - 1140. [Full Text] [PDF]
|
|
|
|
|
|
K. Swedberg Review: Effective Implementation of the New ESC Guidelines for the Management of Chronic Heart Failure in Routine Clinical Practice Journal of Renin-Angiotensin-Aldosterone System, June 1, 2005; 6(2_suppl): S6 - S10. [Abstract] [PDF]
|
|
|
|
|
|
D. M. Roden and R. Temple The US Food and Drug Administration Cardiorenal Advisory Panel and the Drug Approval Process Circulation, April 5, 2005; 111(13): 1697 - 1702. [Full Text] [PDF]
|
|
|
|
 |
|
 T. L Ripley Valsartan in Chronic Heart Failure Ann. Pharmacother., March 1, 2005; 39(3): 460 - 469. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Reigle Are angiotensin-receptor blockers (ARBs) equivalent to or better than angiotensin-converting enzyme (ACE) inhibitors in the treatment of heart failure? Crit. Care Nurse, December 1, 2004; 24(6): 67 - 69. [Full Text] [PDF]
|
|
|
|
|
|
J. D Coyle, S. F Gardner, and C M. White AUTHORS' REPLY: Ann. Pharmacother., December 1, 2004; 38(12): 2176 - 2177. [Full Text] [PDF]
|
|
|
|
|
|
J. J.V. McMurray, M. A. Pfeffer, K. Swedberg, and V. J. Dzau Which Inhibitor of the Renin-Angiotensin System Should Be Used in Chronic Heart Failure and Acute Myocardial Infarction? Circulation, November 16, 2004; 110(20): 3281 - 3288. [Full Text] [PDF]
|
|
|
|
 |
|
 C. V. Leier Dismantling mandates in the treatment of heart failure J. Am. Coll. Cardiol., November 2, 2004; 44(9): 1831 - 1833. [Full Text] [PDF]
|
|
|
|
|
|
C. N. Gring and G. S. Francis A hard look at angiotensin receptor blockers in heart failure J. Am. Coll. Cardiol., November 2, 2004; 44(9): 1841 - 1846. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Drexler and K. C Wollert Reassessing guidelines for heart failure Journal of Renin-Angiotensin-Aldosterone System, March 1, 2004; 5(1_suppl): S28 - S33. [Abstract] [PDF]
|
|
|
|
|
|
S. Orn and K. Dickstein Neurohormonal inhibition in heart failure, is there no limit? Eur. Heart J., October 1, 2003; 24(19): 1705 - 1706. [Full Text] [PDF]
|
|
|
|
 |
|
 M. G. Shlipak Pharmacotherapy for Heart Failure in Patients with Renal Insufficiency Ann Intern Med, June 3, 2003; 138(11): 917 - 924. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M.A. Weber Angiotensin receptor blockers and the cardiovascular continuum: what future is indicated by recent successes? Eur. Heart J. Suppl., April 1, 2003; 5(suppl_C): C1 - C4. [Abstract] [PDF]
|
|
|
|
|
|
J.N. Cohn Val-HeFT: changing the heart failure horizon Eur. Heart J. Suppl., April 1, 2003; 5(suppl_C): C25 - C28. [Abstract] [PDF]
|
|
|
|
 |
|
 ARB Improves Outcomes in HF Patients Not Treated with ACE Inhibitors Journal Watch Cardiology, December 20, 2002; 2002(1220): 5 - 5. [Full Text]
|
|
| HOME | SUBSCRIPTIONS | CURRENT ISSUE | PAST ISSUES | CARDIOSOURCE | SEARCH | HELP | FEEDBACK |
